Type 2 DiabetesCOMMITTED2-KCNCT06374186
Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City
A study testing Behavioral Intervention with financial rewards and coaching in people with Type 2 Diabetes, run by University of Missouri, Kansas City at 1 site in United States.
Trial summary
This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Behavioral Intervention with financial rewards and coaching
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2024to 12 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with type 2 diabetes
- Age 18 to 65
- Hemoglobin A1c (blood draw or point-of-care) test available within the last 3 months
- Most recent hemoglobin A1c result between 8.0 and 11.0
- Currently receiving treatment for diabetes by a licensed healthcare provider.
- Reliable access to a personal smart phone that is compatible with CGM
- English speaking
Who cannot join
- Type 1 diabetes
- Secondary type 2 diabetes (diagnosis secondary to other medical conditions such as pancreatitis, Cystic Fibrosis, or Cushing disease)
- Prescribed short-acting (mealtime) insulin as part of diabetes treatment plan
- Known or acknowledged active substance use disorder or that would interfere or negatively impact participation in the study
- Diagnosis of a medical/psychiatric condition that would prevent participation in the study (e.g., Intellectual Disability, Alzheimer's disease, Traumatic Brain Injury, Schizophrenia)
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Missouri - Kansas City School of Medicine
Kansas City, Missouri, 64108
About this study
Official title: COntinuous Glucose Monitoring, Contingency Management, and Motivational InTerviewing for Patients With TypE 2 Diabetes in Kansas City
This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment program increases individual adherence to a diabetes treatment plan and improves blood sugar management.
Read the detailed description
A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM. Individuals will be randomized in a 1:1 ratio to the intervention group or the control group. Randomization will be blocked and stratified by long-acting insulin and GLP1 medication use. All participants will be given a Continuous Glucose Monitor (CGM) to assess real-time blood sugar levels and establish CM rewards for those assigned to the treatment group.
- Conditions
- Type 2 Diabetes
- Being tested
- Behavioral Intervention with financial rewards and coaching, Control
- Keywords
- Type 2 Diabetes, Glucose, contingency management, motivational interviewing
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral Intervention with financial rewards and coachingBehavioural
Also called Contingency management and motivational interviewing
Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
ControlBehavioural
Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.
| Study group | Role | What they receive |
|---|---|---|
| Behavioral Intervention with financial rewards and coaching | Experimental | Individuals in the treatment group will receive financial rewards (contingency management) and diabetes coaching (motivational interviewing) in addition to wearing a continuous glucose monitor while receiving their usual diabetes treatment. Receives: Behavioral: Behavioral Intervention with financial rewards and coaching |
| Control | Active comparator | Individuals in the control group will not receive any interventions and will only wear a continuous glucose monitor while receiving their usual diabetes treatment. Receives: Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time in target blood glucose range per CGM
Percent time with blood glucose between 70 to 180 mg/dL
Measured: baseline to 14 weeks
Hemoglobin A1C
laboratory value
Measured: baseline to 12 weeks
Secondary outcomes (5)
Diabetes Quality of Life Brief Inventory
self-report questionnaire
Measured: baseline to 12 weeks
Diabetes Distress Scale
self-report questionnaire
Measured: Baseline to 12 weeks
PROMIS Medication Adherence Scale
self-report questionnaire
Measured: Baseline to 12 weeks
Perceived Dietary Adherence Questionnaire
self-report questionnaire
Measured: Baseline to 12 weeks
Motivation and Confidence Ruler
self-report questionnaire
Measured: Baseline to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2024
- Study start1 May 2024
- Primary completion29 Jul 2025
- Study completion12 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM.
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Missouri, Kansas City
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jared Bruce, PhD, Principal investigator, University of Missouri, Kansas City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06374186
- Sponsor's protocol ID
- 2095072
- Other IDs
- 2095072
- Acronym
- COMMITTED2-KC
- Status last verified
- Jan 2026
- First submitted
- 15 Apr 2024
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COntinuous Glucose Monitoring, Contingency Management, and Motivational InTerviewing for Patients With TypE 2 Diabetes in Kansas City
- ClinicalTrials.gov ID
- NCT06374186
- Acronym / sponsor ID
- COMMITTED2-KC / 2095072
- Conditions
- Type 2 Diabetes
- Keywords
- Type 2 Diabetes, Glucose, contingency management, motivational interviewing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- University of Missouri, Kansas CityUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 29 Jul 2025 (actual)
- Study completion
- 12 Aug 2025 (actual)
- First posted
- 18 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment program increases individual adherence to a diabetes treatment plan and improves blood sugar management.
Detailed description
A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM. Individuals will be randomized in a 1:1 ratio to the intervention group or the control group. Randomization will be blocked and stratified by long-acting insulin and GLP1 medication use. All participants will be given a Continuous Glucose Monitor (CGM) to assess real-time blood sugar levels and establish CM rewards for those assigned to the treatment group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
- Model description
- A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM.
| Arm | Type | Receives |
|---|---|---|
| Behavioral Intervention with financial rewards and coaching | Experimental | Behavioral: Behavioral Intervention with financial rewards and coachingIndividuals in the treatment group will receive financial rewards (contingency management) and diabetes coaching (motivational interviewing) in addition to wearing a continuous glucose monitor while receiving their usual diabetes treatment. |
| Control | Active comparator | Behavioral: ControlIndividuals in the control group will not receive any interventions and will only wear a continuous glucose monitor while receiving their usual diabetes treatment. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Diagnosed with type 2 diabetes
- Age 18 to 65
- Hemoglobin A1c (blood draw or point-of-care) test available within the last 3 months
- Most recent hemoglobin A1c result between 8.0 and 11.0
- Currently receiving treatment for diabetes by a licensed healthcare provider.
Key exclusion criteria (5 listed)
- Type 1 diabetes
- Secondary type 2 diabetes (diagnosis secondary to other medical conditions such as pancreatitis, Cystic Fibrosis, or Cushing disease)
- Prescribed short-acting (mealtime) insulin as part of diabetes treatment plan
- Known or acknowledged active substance use disorder or that would interfere or negatively impact participation in the study
- Diagnosis of a medical/psychiatric condition that would prevent participation in the study (e.g., Intellectual Disability, Alzheimer's disease, Traumatic Brain Injury, Schizophrenia)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioral Intervention with financial rewards and coachingAlso: Contingency management and motivational interviewingParticipants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual. | Behavioural | Behavioral Intervention with financial rewards and coaching |
| ControlParticipants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual. | Behavioural | Control |
Primary outcome
Time in target blood glucose range per CGM
Time frame: baseline to 14 weeks
Percent time with blood glucose between 70 to 180 mg/dL
Hemoglobin A1C
Time frame: baseline to 12 weeks
laboratory value
5 secondary outcomes
Diabetes Quality of Life Brief Inventory
Time frame: baseline to 12 weeks
Diabetes Distress Scale
Time frame: Baseline to 12 weeks
PROMIS Medication Adherence Scale
Time frame: Baseline to 12 weeks
Perceived Dietary Adherence Questionnaire
Time frame: Baseline to 12 weeks
Motivation and Confidence Ruler
Time frame: Baseline to 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jared Bruce, PhD principal investigator
University of Missouri, Kansas City
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Behavioral Intervention with financial rewards and coaching in people with Type 2 Diabetes, run by University of Missouri, Kansas City at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time in target blood glucose range per CGM (time frame: baseline to 14 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.